SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.
SURGE Therapeutics has raised $32.0M in total funding. The most recent round was Series B. The last funding was announced in July 2023.
SURGE Therapeutics's investors include Alumni Ventures, Khosla Ventures, 8VC, Pitango VC, KdT Ventures.
SURGE Therapeutics is headquartered in Cambridge, United States.
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.
SURGE Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SURGE Therapeutics — Funding & Investors." VCBacked, July 19, 2023, https://www.vcbacked.co/company/surge-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). SURGE Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/surge-therapeutics
{{cite web |title=SURGE Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/surge-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated